{"id":815403,"date":"2025-02-20T07:04:34","date_gmt":"2025-02-20T12:04:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/"},"modified":"2025-02-20T07:04:34","modified_gmt":"2025-02-20T12:04:34","slug":"an2-therapeutics-to-participate-at-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/","title":{"rendered":"AN2 Therapeutics to Participate at Upcoming Investor Conferences"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>AN2 Therapeutics to Participate at Upcoming Investor Conferences<\/b><\/p>\n<p>MENLO PARK, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March.\n<\/p>\n<p>\nDetails of the events are as follows:\n<\/p>\n<p>\nTD Cowen 45<sup>th<\/sup> Annual Health Care Conference\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nEric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Monday, March 3, 2025 at 2:30 pm ET, and members of management will be available for 1X1 meetings.\n<\/li>\n<\/ul>\n<p>\nLeerink Partners Global Healthcare Conference\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nMembers of management will be available for 1X1 meetings on Wednesday, March 12, 2025.\n<\/li>\n<\/ul>\n<p>\nA webcast of the Cowen Health Care Conference presentation can be accessed on the Investors section of the AN2 Therapeutics website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.an2therapeutics.com&amp;esheet=54210535&amp;newsitemid=20250220323899&amp;lan=en-US&amp;anchor=www.an2therapeutics.com&amp;index=1&amp;md5=83199e7094fe259e84d2435da01f0e2e\">www.an2therapeutics.com<\/a>. An archived replay will be available for at least 30 days following the presentation.\n<\/p>\n<p><b>About AN2 Therapeutics, Inc.<\/b><\/p>\n<p>\nAN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.an2therapeutics.com&amp;esheet=54210535&amp;newsitemid=20250220323899&amp;lan=en-US&amp;anchor=www.an2therapeutics.com&amp;index=2&amp;md5=117886c9b1ab51b4ca002feebcad9f76\">www.an2therapeutics.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220323899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250220323899\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250220323899\/en\/<\/a><\/span><\/p>\n<p><b>COMPANY CONTACT:<br \/>\n<\/b><br \/>Lucy O. Day<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:l.day@an2therapeutics.com\">l.day@an2therapeutics.com<\/a><\/p>\n<p><b>INVESTOR AND MEDIA CONTACT:<br \/>\n<\/b><br \/>Anne Bowdidge<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@an2therapeutics.com\">ir@an2therapeutics.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Massachusetts California Florida<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Infectious Diseases Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250220323899\/en\/1863965\/3\/AN2_Therapeutics_Press_Release_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>AN2 Therapeutics to Participate at Upcoming Investor Conferences MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March. Details of the events are as follows: TD Cowen 45th Annual Health Care Conference Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Monday, March 3, 2025 at 2:30 pm ET, and members of management will be available for 1X1 meetings. Leerink Partners Global Healthcare Conference Members of management will be available for 1X1 meetings on Wednesday, March 12, 2025. A webcast of the Cowen Health Care &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AN2 Therapeutics to Participate at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-815403","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AN2 Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AN2 Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AN2 Therapeutics to Participate at Upcoming Investor Conferences MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March. Details of the events are as follows: TD Cowen 45th Annual Health Care Conference Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Monday, March 3, 2025 at 2:30 pm ET, and members of management will be available for 1X1 meetings. Leerink Partners Global Healthcare Conference Members of management will be available for 1X1 meetings on Wednesday, March 12, 2025. A webcast of the Cowen Health Care &hellip; Continue reading &quot;AN2 Therapeutics to Participate at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-20T12:04:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220323899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AN2 Therapeutics to Participate at Upcoming Investor Conferences\",\"datePublished\":\"2025-02-20T12:04:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\\\/\"},\"wordCount\":279,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250220323899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\\\/\",\"name\":\"AN2 Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250220323899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-02-20T12:04:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250220323899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250220323899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AN2 Therapeutics to Participate at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AN2 Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"AN2 Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk","og_description":"AN2 Therapeutics to Participate at Upcoming Investor Conferences MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March. Details of the events are as follows: TD Cowen 45th Annual Health Care Conference Eric Easom, Co-Founder, Chairman, President and CEO will provide a corporate overview on Monday, March 3, 2025 at 2:30 pm ET, and members of management will be available for 1X1 meetings. Leerink Partners Global Healthcare Conference Members of management will be available for 1X1 meetings on Wednesday, March 12, 2025. A webcast of the Cowen Health Care &hellip; Continue reading \"AN2 Therapeutics to Participate at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-20T12:04:34+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220323899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AN2 Therapeutics to Participate at Upcoming Investor Conferences","datePublished":"2025-02-20T12:04:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/"},"wordCount":279,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220323899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/","name":"AN2 Therapeutics to Participate at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220323899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-02-20T12:04:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220323899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250220323899r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/an2-therapeutics-to-participate-at-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AN2 Therapeutics to Participate at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=815403"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815403\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=815403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=815403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=815403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}